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Abstract: 
Prototype contact lens cases have been prepared which are coated with an 
Oligon antimicrobial silicone formulation. The Oligon silicone coating 
incorporates a conductive additive, silver and platinum powder to set up an 
electrochemical system, that when contacted by chloride ions found in 
physiological saline, releases silver ions into the surrounding aqueous 
medium. Silver ions have been reported in the literature to be a potent 
antimicrobial agent, showing effectiveness against both gram-positive and 
gram-negative bacteria as well as yeasts and molds. This study was 
designed to study the effectiveness of Oligon coated contact lens cases 
against FDA (Food and Drug Administration) approved Stand Alone 
protocol for disinfecting contact lenses for the following organisms: 
Psuedomonas aeruginosa, Serratia marcenscens, Staphylococcus aureus, 
Candida albicans, and Fusarium solani. The results of the study conclude 
that the Oligon cases do not meet the 8 hour FDA stand alone criteria for 
any of the organisms tested, but with modification, may be an exciting new 
frontier for the future of contact lens disinfection. 
Introduction: 
The traditional contact lens care regimen, although functional, has 
problems with compliance, hypersensitivy reactions to preservatives in 
solutions, and the effectiveness of microbial reduction. These problems 
have resulted in infections of the eye. Thus, there is a need for a 
disinfection method that is easy to use, preservative free, and successful in 
reducing different kinds of organisms on both contact lenses and cases. 
Preliminary studies have been done on a prototype contact lens case and 
have suggested that this type of disinfection method can kill contaminating 
microorganisms and would be easy to use. 
The prototype contact lens cases, developed by Oligon, have a silicone 
coating on the well surface that has platinum and silver ions impregnated in 
it. Upon contact with physiological saline, the silver ions are released into 
the aqueous medium by an electrochemical current initiated by the chloride 
ions in the saline. This process is known as oligodynamic iontophoresis. 
Free silver ions have been used through the ages and have been shown in 
the literature to be a powerful antimicrobial agent. Silver was first used in 
ancient Roman times as the lining for aqueducts, and is currently utilized as 
an antimicrobial agent in catheters. A number of patents are filed which are 
attempting to expand the medical uses of this technology, including 
implantable, bacteriocidal medical devices. 
Preliminary studies have shown promise in the use of Oligon technology in 
contact lens care. The purpose of our study was to determine the 
effectiveness of the Oligon coated prototype cases using the FDA Stand 
Alone Protocol for contact lens disinfection. To meet the Stand Alone 
criteria, no other methods may be used to alter the lenses, including digital 
or mechanical rubbing, and there must be a kill rate of not less than 3 log 
units for the bacteria, and not less than 1 log unit for yeasts and molds, in 
an 8 hour time frame. The FDA dictates that the care system must be 
effective against the following organisms: Pseudomonas, Staphylococcus, 
Fusarium, Candida, and Serratia. (See Appendix for complete FDA Stand-
Alone Procedures) 
Methods: 
To test the Oligon disinfection lens cases, Imp limed provided 10 coated 
Alcon standard lens cases (there are 2 contact lens wells per case.) In 
addition we acquired 10 other Alcon standard cases, brand new and with 
out modifications. Each contact lens well was treated as an individual test, 
with 8 wells ( 4 cases) for each organism, 2 coated cases and 2 non-coated 
controls. 
Each well was inoculated with a microorganism and a 100 ul initial sample 
was taken. In order to gain countable plates 4, 1: 10 dilutions were 
performed and individually plated on the appropriate agar. (See Appendix 
Media) This constituted time 0 (zero.) To adhere to a strict timing regimen, 
another well was inoculated at exactly 5 minutes after the first well, also 
indicating time 0 (zero) for that well. (See Appendix Timing.) The 5 minute 
delay was necessary to perform the dilutions and plating, and obtain the 
materials needed for the next test. At times 2, 4, 6, 8, and 32 hours, 100 ul 
samples were taken from the wells, and again, 4, 1:10 dilutions were 
performed and plated for each sample. Given the large quantity of agar 
plates, test tubes, pipettes, and space needed, we divided our experiment 
into 2 days. Staphylococcus and Pseudomonas were tested on the first 
day, Serratia, Candida and Fusarium, on the second. Plate counts were 
obtained for the bacterial plates at 48 hours and 72 hours for the yeasts and 
molds. 
The following procedures will be discussed in detail: (A) preparation of 
media, (B) preparation of inocula, (C) inoculation of contact lens wells, (D) 
serial dilutions and plating, and (E) plate counts. 
A. Preparation of Media- Agar plates (TSA, PDA, SDA) were 
prepared 2 days prior to the experiment and were made to incorporate a 
Diffco neutralizing buffer. The procedure is as follows: 
(a) Mix TSA, PDA, and SDA medium to include the Diffco 
neutralizing buffer at 5.2 gm/L. 
(b) Enough media is required for 200 plates per organism (8 
wells, 4 control wells and 4 test wells, X 6 sample times, X 4 
dilutions per sample= 192 plates.) 
(c) Media preparations are placed in 1000 ml Erlenmeyer 
flasks for ease in pouring, and autoclaved at pressure and 
temperature for 30 minutes. 
(d) From the autoclave, the flasks are transferred to a 
controlled temperature water bath and allowed to equalize at 
temperature, 46-4 7 C, for 1 hour prior to pouring. 
(e) Completed plates are marked and coded with a marking 
pen denoting organism, control or test group, well number and 
time, and refrigerated until 2 hours prior to use. 
As a time saving procedure, test tubes containing sterile saline may also be 
made and pi petted prior to running the experiment. For samples taken every 
5 minutes, 4 test tubes of sterile saline are required. The first dilution 
requires 100 ul of inocula to be added to 9.9 ml of sterile saline. Then, 3 
dilutions are performed, adding 1 ml of inocula to 9 ml of sterile saline. 
Thus, to perform the whole experiment (8 test wells X 5 organisms X 6 
sample times X 4 dilutions per sample), 960 test tubes of sterile saline are 
required, 240 test tubes with 9.9 ml of saline and 720 test tubes with 9.0 ml 
of saline. Properly labeling and storing the test tubes in racks, in groups of 
4, will avoid confusion and increase the efficiency of the experiment. 
B. Preparation of Inocula- ATCC organisms, shipped in glass vials, 
need to be rehydrated prior to use. Sterile, physiological saline is sufficient 
to suspend the mixture in the vial. This mixture is then transferred to the 
appropriate agar plate and allowed to incubate for the required time. (See 
Appendix Media) Given the longer incubating time for Fusarium solani, it is 
appropriate to start with that organism up to 14 days prior to use. 
(a) 8 agar plates per organism will be required for preparation 
of the inocula, 2 to plate the rehydrated ATCC mixture and 6 to 
provide isolated colonies. 
(b) After the required incubation time to grow the ATCC vial 
organisms, streak plates are prepared to provide isolated 
colonies. Streak a plate from the culture slant in quadrants, 
flaming the inoculating loop before each streak. Repeat this 
process to provide 6 plates total, and incubate. For the 
bacteria, this should be done 24-48 hours prior to starting the 
experiment. 
(c) The day of the experiment, isolated colonies are harvested 
with a sterile cotton swab moistened with sterile saline. 
Transfer the inoculated swab to a test tube containing sterile 
saline and vortex, allowing the swab to rotate freely. 
(d) Repeat this process until the media appears turbid and 
milky in appearance. This should represent approximately a 
10 7 to 10 9 solution. If lab equipment allows, spectroscopy or 
a McFarland standard may be applied to verify bacterial 
concentration in solution. (See Appendix McFarland) 
(e) To obtain spores from Fusarium solani, hyphae are 
harvested with a flamed loop and transferred to sterile saline. 
This mixture is vortexed and centrifuged. Both the supernate 
and substrate are then washed with more sterile saline and 
filtered through fine cheesecloth. Repeat the washing process 
3 to 5 times to obtain inocula consisting of mostly spores. 
(f) Vials of inocula are stored at 20-25 C prior to use, and 
protected from light and contaminates. 
C. Inoculation of Contact Lens Wells- Prepared vials of inocula are 
stored at an approximately, or if known through prior testing, 109 
concentration. FDA protocol dictates that test inocula be between 105 to 
106 cfu/ml and that the volume of inocula not exceed 1% of the sample 
volume. (p 96 C 1) The test volume of the contact lens is set at 2 ml, thus 
serial dilutions are required to set the test inocula in the wells to the required 
concentration and volume. 
(a) Vials of inocula are vortexed to ensure all bacteria are in 
suspension. 1 ml of the approximate 109 inocula is pi petted 
into 9 ml of sterile saline and vortexed. This represents a 1/1 0 
dilution and a final concentration of about 1 08· 
(b) Each contact lens well is to be swabbed with isopropyl 
alcohol prior to use. After swabbing, the cases are allowed to 
air dry under a sterile hood for 1 hour. 
(c) Upon drying and at test time zero (0) (See Appendix 
Timing) for the lens well to be tested, 2 ml of sterile saline are 
pi petted into the appropriate contact lens test well. 20 ul of the 
108 inocula is added to the lens well with a 10-100 ul Ependorf 
Research Pipette. This represents a 11100 dilution leaving the 
initial test concentration in the well at about 1 06 cfulml. 
(d) To insure dispersion of the inocula, cases are capped and 
gently agitated in a figure-8 pattern for 1 minute. 
D. Serial Dilutions and Plating- At the instant the 20 ul inocula is 
transferred to the first test well, the timer is initiated. This is time zero and 
5 minutes remain before the next test well is to be inoculated. (See 
Appendix Time) Quickness, speed and accuracy are necessary to maintain 
the strict time requirements of this experiment. 
(a) After the 1 minute of agitating the inoculated test well to 
ensure proper mixing, 100 ul are extracted from the lens well 
using the 10-1 00 ul Ependorf Scientific Research pipette and 
added to 9.9 ml of sterile saline. This mixture is vortexed and 
represents 1/100 dilution, and a concentration of 104 cfulml. 
(b) Using a 1 ml pipette, 1 ml of the 104 solution is transferred 
to an appropriate agar plate and spread with a sterile glass rod. 
With the same pipette, another 1 ml of this solution is 
transferred to 9 ml of sterile saline and vortexed. This 
represents a 1/10 dilution, and a concentration of 103• 
(c) The process outlined in (b) is repeated 2 more times, using 
a new, sterile pipette each time, to obtain 1 ml plated samples 
each of concentrations representing 102 and 101 cfu/ml. 
(d) Inoculated plates are carefully transferred to a holding area 
and materials are gathered for the next test well to be 
inoculated at exactly time 5 minutes. Processes (a)-( d) are 
repeated for each well at each sampling time (zero, 2, 4, 6, 8, 
and 32 hours.) 
E. Plate Counts- Plates are allowed to sit upright to dry until no 
liquid is detectable on the surface of the agar. At that point, plates are 
inverted and transferred to a temperature controlled incubator for the 
appropriate time (See Appendix Media) Plate counts were determined by 
visually counting the number of cfu (colony forming units) per plate. 
Countable plates had between 30 to 300 cfu/plate for bacteria and yeast and 
8 to 80 cfu/plate for molds. Bacterial plates that were determined to be to 
numerous to count (TNTC) were recorded as greater than 3.00 x 107, since 
that was the sensitivity of our test. Bacterial plates that were too few to 
count (TFTC), or showed no growth at all, were recorded as less than 30 
cfu. 
Data: 
The number of cfu were determined for each lens well at each sample 
period. By determining the initial concentration, at time zero, it was possible 
to determine the concentration of bacteria in our original inoculum. Since 
the same inoculum was used for each of the 8 test wells for that organism, 
mean concentrations and kill rates were determined for the like test groups 
( 4 Oligon vs. 4 control.) The graphs show how individual wells did 
through time, as well as the means of all 4 wells. 
FDA protocol dictates that to meet Stand Alone criteria, contact lens care 
products must show a kill rate of at least 3 log units. Our graphs were 
designed in a log versus time format to determine if that criterion was met. 
Due to difficulties with handling Fusarium in the lab and inconsistant data, 
those numbers were excluded and, subsequently, not graphed. 
Discussion: 
All of the organisms tested under the Oligon test case failed to meet the 
FDA stand alone criteria for contact lens disinfection for any organism. 
The Oligon cases failed to kill the minimum 3 log units of any organism 
tested in the 8 hour test period. However, the Oligon test cases did have 
higher kill rates for some organisms when compared with the control, but 
not within 8 hours. For example, Oligon killed Pseudomonas with a greater 
than 3 log kill rate, but not until the 32 hour test period. 
Fusarium data was collected but was not graphed. The number of cfu 
varied greatly between individual test wells. Fusarium has proven to be a 
difficult organism to work with in this type of setting. The challenge with 
Fusarium is, first, to ensure that the inoculating media has a sufficient 
number of spores, and ndt hyphae. Secondly, there was an apparent 
problem with ensuring adequate mixing when samples were taken and 
possible clumping of the spores in the test wells. This showed in the data 
by having wells sampled early in the experiment that showed no growth and 
later in the experiment showing cfu that were too numerous to count. In 
handling Fusarium, future researchers should concentrate on finding a way 
to ensure sufficient disbursement of the spores and on a more accurate 
method of determining the spore concentration in the initial inoculum. 
The bacteria tested also showed slight variations between individual test 
wells, however, they were minimal and generally followed the same pattern 
through time. This, again, may point to a problem with mixing. Other 
methods to employ to ensure proper mixing may be as simple as keeping 
test cases on an agitated surface between sampling times. 
Pseudomonas, one of the most pathological organisms tested and most 
relevant to contact lens induced infections of the eye, actually showed the 
best results. The Oligon test cases showed a greater than 4 log unit kill rate 
over 32 hours. This is combined with the kill rate of the control wells of 
approximately 1 log of reduction over the same time period. The 
Pseudomonas data are also nice, since the initial concentration of organisms 
was within the FDA approved parameters for inocula at 107 cfu. Our lab 
was not equipped with a spectrophotometer and we were unable to handle 
the toxic barium chloride and sulfuric acid required to make the McFarland 
standard. Future researchers should employ either of the two methods to 
ensure that the starting inoculum is within FDA standards. Our method 
was to add organisms until the media became turbid and we assumed that 
we would be in the range. That method proved effective for Pseudomonas 
and Serratia, but not Staphylococcus, Candida or Fusarium. 
Staphylococcus aureus is another organism that can cause ocular 
infections. Our data show that the Oligon test cases did not perform better 
than the control cases in eliminating Staphylococcus through an 8 hour test 
period. At time 32 hours, however, the Oligon control group showed at 
least 1 log kill rate more than the control. One of our difficulties with our 
experiment in working with Staphylococcus was our initial inoculum 
concentration was too low. This might have effected the final outcome of 
the data, since it might have been easier to show a higher kill rate if more of 
the bacteria were available to be eliminated. There is also the consideration 
of time with Staphylococcus, it could be that with our test cases, we were 
able to meet the 3 log kill rate, but just not within the 8 hour period. Future 
researchers should, again, be certain of the inoculum concentration before 
starting the experiment. 
Unlike Staphylococcus, where our problem was too few of the organism 
starting out, Serratia was the opposite. We possibly had too many of the 
organism starting out. Limited by our dilutions, we were only able to 
ascertain that there were greater than 10 7 cfu of Serratia in each of the 
Oligon and control wells at the start of the experiment. Although the 
number of cfu's of Serratia stayed too numerous to count for the control 
group throughout the experiment, the Oligon group showed a greater than 1 
log kill rate, on average, by time 3 2 hours. One interesting item to note 
about the Oligon test wells is that 2 of the wells consistently showed better 
results than the other two wells, actually showing nearly a 4 log reduction 
by time 32 hours. That leads us to believe that maybe there was a slight 
variation in the coating process of the cases that lead to the differences 
within the test group. 
Candida, the yeast, performed much the same way as Staphylococcus. 
There were, perhaps, too few of the organism starting out. The Oligon 
group performed slightly better through time than did the control, but not 
near the 3 log kill rate. By time 32 hours, the Oligon group was almost 2 
logs better than the control, however, the mean number of organisms 
increased at time 32 for the control. This suggests, like Fusarium, that 
there were possibly some problems with mixing and sampling. 
For all organisms tested, save for Fusarium, the Oligon test cases 
performed better than the controls. In the case of Pseudomonas, and 
possibly Staphylococcus, the performance was such that the 3 log units of 
reduction were met for the FDA requirement. The problem with it was in 
the time that it was meet, that is, not within 8 hours. For a first experiment 
with this new and promising method of disinfecting contact lenses, we 
should all be excited. There are a number of studies and trials that need to 
be performed before this becomes a viable option for contact lens 
disinfection for the consumer. We believe that current studies should 
center on improvements on the time release capabilities of the Oligon 
coating and control of the silver ion concentration. Future experiments may 
include: the formulation of the silicon coating, the coating process itself, and 
the type and pH of solution/saline used in the well. 
We strongly feel that the Oligon method of contact lens disinfection is the 
frontier for contact lens care of the future. The benefits to the contact lens 
wearer will be greater ease of use, better compliance and less secondary 
ocular complications to contact lens wear, namely, allergic reactions to 
preserved saline and infections of the eye. With a concerted effort by 
Oligon to improve on an exciting oligodynamic technology and the ability of 
outside labs to improve on our method to test the efficacy of the cases, we 
can make this technology the way of contact lens care of the future. 
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Appendix-Materials 
Organisms: (by corresponding A TCC number) 
#06538 
#09027 
#10231 
#13880 
#36031 
Staph Aureus 
Pseudomonas aeruginsoa 
Candida Albicans 
Serratia marcescens 
Fursarium solani 
Pipettes: (Order numbers correspond to Daigger Supply Catalog) 
1 
300 
2000 
1 
Ependorf Research Pipette 10-100 ul 
Eppendorf Disposable Pipette Tips 
Disposable Pipettes 1 ml (graduated to tip) 
Pipette Aid 
#PX20541D 
#PX20561XB 
#PX202656 
#PX20460F 
Agar Plates: (Order numbers correspond to Daigger Supply Catalog) 
1000 Petri Dishes 1 00x20 #PX7116B 
Agar/Neutralizer: (Order numbers correspond to VWR Scientific Products Supply 
Catalog) 
1000 grams 
500 grams 
500 grams 
200 grams 
Tryptone Soya Agar (TSA) 
Potato Dextrose Agar (PDA) 
Sabouraud Dextrose Agar (SDA) 
Diffco Buffer (Neutralizer) 
Other Equipment needed: 
#DF0369-17 
#DF0013-17 
#DF0109-17 
#DF0362-15 
-Controlled temperature water bath (for fabricating agar plates) 
-Controlled climate incubators 
-Sterilizer/ Autoclave 
-large flasks and distilled water (for making sterile water) 
-approximately 1000 15 ml test tubes with racks 
-approximately 50 glass rod plate spreaders-reusable if flamed in ETOH 
-Autoclavable Biohazard Bags 
-a buson burner 
-stop watch 
-lab disinfectant 
-electric vortex mixer 
Appendix-Media 
Media and Incubation Conditions for Growth of Challenge Organisms 
Or2anisrn Mediu.m Temri(Cl Incubation Time 
P. aeruginosa TSA 30-35 18-24 hours 
S. aureus TSA 30-35 18-24 hours 
S. marcescens TSA 30-35 18-24 hours 
C. albicans SDA 20-25 42-48 hours or 
' SDA 30-35 18-24 hours 
F. solani PDA 20-25 10-14 days 
Apendix- Timing 
Example of Experiment Set-Up 
for 2 test organisms 
PT= Pseudomonas Test Wells 
PC= Pseudomonas Control Wells 
ST= Staph Test Wells 
SC= Staph Control Wells 
Time Zero 
(table shows test organism and well number and time in hours/minutes) 
PT (time) 5 minute PC (time) 5 minute ST (time) 5 minute SC (time) 
break break break 
0:20 0:45 1:05 
PTl 0:00 PC1 0:25 STl 0:45 SCI 1:10 
PT2 0:05 PC2 0:30 ST2 0:50 SC2 1:15 
PT3 0:10 PC3 0:35 ST3 0:55 SC3 1:20 
PT4 0:15 PC4 0:40 ST4 1:00 SC4 1:25 
Lab Prep Time 1:30 to 1:55 
Time 2 Hours 
PT (time) 5 minute PC (time) 5 minute ST (time) 5 minute SC (time) 
break break break 
2:20 3:45 3:05 
PT1 2:00 PCl 2:25 ST1 2:45 SCI 3:10 
PT2 2:05 PC2 2:30 ST2 2:50 SC2 3:15 
PT3 2:10 PC3 2:35 ST3 2:55 SC3 3:20 
PT4 2:15 PC4 2:40 ST4 3:00 SC4 3:25 
Repeat Process for Sample Times 6, 8 and 32 hours 
Appendix D 
McFarland nephelometer barium sulfate standards 
Procedure: 
(a) Prepare 1% aqueous barium chloride and 1% aqueous sulferic 
acid solutions. 
(b) Add the amounts indicated in Table 1 to clean, dry ampoules. 
Ampoules should have the smae diameter as the test tube to be used 
in subsequent density determinations. 
(c) Seal the ampoules and label them. 
Preparation of standards: 
Tube 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
BaCl2 Sulfuric Acid 
1% (ml) 1% (ml) 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1.0 
9.9 
9.8 
9.7 
9.6 
9.5 
9.4 
9.3 
9.2 
9.1 
9.0 
Bacteria Density 
Cmillionfml) 
300 
600 
900 
1,200 
1,500 
1,800 
2,100 
2,400 
2,700 
3,000 
MICRO--APPENDIX B 
DISINFECTION EFFICACY TESTING 
PART 1. STAND-ALONE PROCEDURE FOR DISINFECTING PRODUCTS 
I. PRINCIPLE 
The stand-alone test challenges a disinfecting product with a standard 
inoculum of a representative range of microorganisms and establishes the 
extent of viability loss at pre-determined time intervals comparable with 
those during which the product may be used. The size of the microbial 
challenge chosen in this test is not intended to be representative of the 
likely challenge in practice, but to provide countable numbers from which 
estimation of the rate and extent of viability loss can be determined. 
In carrying out the test for antimicrobial activity, the qualitative 
composition of the product should be known at the time of testing by 
either analytical testing or extrapolation. 
Appropriate measures should be taken to inactivate or remove residual 
antimicrobial, agents during culturing and counting of survivors and the 
effectiveness of these measures should be validated and the action of 
this process during the test should be demonstrated by the construction 
of suitable controls. 
Three batches of product should be tested. Each batch of product should 
be tested with a separate inoculum preparation for each challenge 
organism. 
II. MATERIALS AND REAGENTS 
A. Test organisms 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Serratia marcescens 
Candida albicans 
Fusarium solani 
B. Test Media 
Potato Dextrose Agar (PDA) 
Tryptone Soya Broth (TSB) 
Tryptone Soya Agar (TSA) 
Sabouraud Dextrose Agar (SDA) 
NCIMB 8626 
NCTC 10788 
NCTC 10211 
NCTC 3179 
ATCC 9027 
ATCC 6538 
ATCC 13880 
ATCC 10231 
ATCC 36031 
Dulbecco's Phosphate Buffered Saline without calcium chloride and 
magnesium chloride (DPBS): 200 mg/L KCl, 200 mg/L KH2P0 4 , 
8000 mg/L NaCl, and 2,160 mg/L Na2HP04 •7H2 0 or a suitable diluent. 
Dulbecco•s Phosphate Buffered Saline plus 0.05% w/v polysorbate 80 
(DPBST) or a suitable diluent. 
Validated neutralizing agents/media required (e.g., Dey-Engley 
Neutralizing Broth and Agar). 
C. Test Equipment 
Sterile pipettes, glass beads, swabs, tubes, 100 X 20 rnrn petri 
dishes, etc., as required. Suitable instruments for 
spectrophotometric determination of cell density, for colony 
counting, and for centrifugation. 
D. Test Samples 
Product samples to be tested should be representative of the 
product to be marketed. Aliquots should be taken directly from 
the final product container immediately prior to testing. 
III. TEST METHOD 
A. Culture Maintenance 
9') 
Cultures should be maintained in the manner recommended by the 
curator of the appropriate culture collection. Cultures should be 
no greater than five passes removed from the depository stock 
(ATCC,, NCIB, NCTC, NCPF or other recognized culture depository . ) 
B. Preparation of Microbial Challenge (Inoculum) 
Test organisms should be cultured on agar as in Table 1. 
r____-------------------~T=a-~-. ~1~----------~-----------------
Media and Incubation conditions for Growth of Challenge Organisms 
Organism Medium Temp (°C) Incubation Time 
P. aeruginosa TSA 30-35 18-24 hrs 
s. au reus TSA 30-35 18-24 hrs 
s. marcescens TSA 30-35 18-24 hrs 
c . albicans SDA 20-25 42-48 hrs or 
SDA 30-35 18-24 hrs 
F . sol ani FDA 20-25 10-±-i_~s 
all cultures, use sterile DPBST or a suitable diluent , 
washing the surface growth and transfer to a suitable vessel. The 
spore suspensions may be filtered through sterile glass wool, 
cotton gauze or cheese cloth to remove hyphal fragments. 
After harvesting, the cultured organisms may be washed using 
centrifugation. If centrifugation is used, each centrifugation 
should be conducted at 2-25°C for no longer than 10 minutes at 
4000 x g or less. The bacterial suspensions may be filtered 
<e.g., 3 - 5 ~pore size) to produce a single cell dispersion . 
All challenge cell suspensions should then be adjusted with DPBST 
or other suitable diluent to 1 X 107 - 108 cfu/ml . The 
approximate cell concentration may be estimated by measuring the 
turbidity of the suspension or a dilution of the suspens i on using 
a spectrophotometer. The actual concentration of cfu/ml should be 
determined for each suspension by the plate count method at the 
time of the test. 
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Bacterial and yeast cell suspensions should be used on the day of 
preparation. Bacterial and yeast cell may lose viability and 
resistance if not used on day of preparation. Spore suspension~. 
may be used up to 7 days following preparation by storage under 
refrigeration (Avg. 4~2°C). 
C. Test Procedure 
1. Prepare one tube containing a minimum of 10 ml of test 
solution per challenge organism. Inoculate the sample tube 
of the product to be tested with a suspension of test 
organisms sufficient to provide a final count of 1.0 X 105 -
1.0 X 106 cfu/ml. The volume of inoculum should not exceed 
1% of the sample volume. Ensure dispersion of the inoculum 
by adequate mixing. 
2. Store inoculated product at 20-25°C. Temperature should be 
monitored using a calibrated device and documented. If 
sensitive to light the product should be protected during 
the period of the test. 
3. Take 1.0 ml aliquots of the inoculated product for 
determination of viable count at 25%, 50%, 75% and 100% of 
the minimum recommended disinfection time for all organisms, 
and, in addition, at not less than 4 times the minimum 
recommended disinfection time for yeast and mold. Where 
overnight disinfection is recommended, disinfection time is 
taken to be 8 hours. 
4. Subject 1.0 ml aliquots removed at the specified time 
intervals to a suitable series of decimal dilutions in 
validated neutralizing media. Mix suspension well by 
vortexing vigorously and incubate for a suitable period of 
time to allow for neutralization. 
If the antimicrobial agent(s) in the formulation cannot be 
adequately inactivated or neutralized it may be eliminated 
using a validated membrane filtration procedure (e.g., 
Micro--Appendix D) . 
5. Determine the viable count of organisms in appropriate 
dilutions by preparation of triplicate plates (unless 
otherwise justified) of a suitable recovery medium (e.g., 
TSA for bacteria and SDA for mold and yeast). 
Where membrane filtration has been employed to 
remove/neutralize antimicrobial agents, membranes should be 
cultured on these media as appropriate. The agar for pou~ 
plates should be kept between 40-50°C prior to pouring. Tl1e 
agar media used for determination of viable counts may also 
contain antimicrobial inactivators or neutralizers if 
required. 
6. Incubate bacterial recovery plates at 30-35°C for ~-4 days. 
Incubate yeast at 20-25°C or 30-35°C for 3-5 day§ and mold 
recovery plates at 20~25°C for 3-7 days. 
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7. Determine the average number of cfu on countable plates. 
Countable plates refer to 30 to 300 cfu / plate for bac teria 
and y east, and 8 to 80 cfu / plate for mold except when 
co l onies are observed only for the 10° or 10-1 dilution 
plates. Calculate microbial reduction at the specified time 
points. 
D. Controls 
1. I noculum Control 
An inoculum count is made by dispersing an identical aliquot 
of the inoculum into the same volume of suitable diluent 
(e.g., DPBST) as used in Part 1:III.C.1 to achieve a final 
concentration of 1.0 X 105 - 1.0 X 106 cfu/ml . The volume of 
inoculum should not exceed 1% of the sample volume. Ensure 
dispersion of the inoculum by adequate mixing. This control 
sample should be evaluated for cfu/ml at the beginning of 
the test. This serves to demonstrate the suitability of the 
medium used for growth of the test organism and provides an 
estimate of the initial inoculum concentration. 
2 . Recovery medium control 
Prepare a 1/10 dilution of the disinfecting solution in the 
validated neutralizing broth (1 ml into 9 ml). If a greater 
dilution of the test solution is required to achieve 
neutralization, the latter dilution should be used. Prepare 
a second control tube with 10 ml of a suitable diluent 
(e.g., TSB). Inoculate the tubes with sufficient inoculum 
to result in 10-100 cfu of challenge organism per plate. 
Incubate for an appropriate period of time at ambient 
temperature. Plate the appropriate aliquot from each tube 
onto the recovery agar plates in triplicate unless otherwise 
justified. 
The recovery in the neutralizer broth should be at least 50% 
of the recovery in the second control tube. This control 
should be performed for each challenge organism. 
IV. PERFORMANCE REQUIREMENT 
A. Control Specification 
If any control value falls out of specification, the associated 
test is invalid and should be repeated. 
B . Primary Criteria (See Part 2, Table 2) 
1. Bacteria 
The number of organisms recovered per ml should be reduced 
by a mean value of not less than 3.0 logs within the minimum 
recommended disinfection period. 
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2. Molds and Yeasts 
The number of organisms recovered per ml should be reduced 
by a mean value of not less than 1.0 log within the minimum 
recommended disinfection time with no increase at not less 
than four times the minimum recommended disinfection time. 
c. Secondary Criteria (See Part 2, Table 2) 
Products failing to meet the criteria in Part I:IV.B.1 or 
Part l:IV.B.2 may be evaluated by the regimen test procedure 
described below, provided there is a combined log reduction for 
the means of all bacteria of not less than 5.0 within the 
recommended disinfection period. The minimum acceptable mean log 
reduction for any single bacterial type is 1.0. Stasis for the 
yeast and mold (within an experimental error of +0.5 log) should 
be observed for the recommended disinfection period. 
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PART 2. REGI~ffiN PROCEDURE FOR DISINFECTING REGIMENS 
I. PRINCIPLE 
This procedure is applicable to multi-functional disinfection regimens 
which may include the steps of cleaning, rinsing, and soaking. In 
carrying out the regimen test procedure, the products should be used in 
the manner and quantity recommended in product labeling and/or patient 
instructions. The test challenges the proposed disinfection regimen 
with a standard inoculum of a representative range of microorganisms. 
The inoculum is carried through the various stages of the regimen by 
preliminary application to contact lenses. 
The disinfecting stage of any proposed contact lens disinfection regimen 
evaluated by this test should have demonstrated minimum antimicrobial 
activity by the Stand-Alone Procedure as indicated for Regimen 
Qualification. 
In carrying out the test, qualitative and quantitative composition of 
all products used in the test regimen should be known at the time of 
testing, either by analytical testing or extrapolation. 
Appropriate measures should be taken to inactivate or remove residual 
antimicrobial agents during culturing and counting of the challenge 
organism and the effectiveness of these measures should be demonstrated 
by the construction of suitable controls. 
A minimum of three lots of product should be tested. Each lot of 
product should be tested with a separate inoculum preparation for each 
challenge organism. 
II. MATERIALS AND REAGENTS 
A. Test Organisms 
!Pseudomonas aeruginosa Staphylococcus aureus Serratia marcescens Candida albicans 
( :usarium solani 
~ d " B. Test Me la 
NCIMB 
NCTC 
NCTC 
NCPF 
( Tryptone Soya Broth (TSB) Tryptone Soya Agar (TSA) 
Sabouraud Dextrose Agar (SDA) 
Potato-Dextrose Agar (PDA) 
8626 
10788 
10211 
3179 
ATCC 9027 
ATCC 6538 
ATCC 13880 
ATCC 10231 
ATCC 36031 
Dulbecco•s Phosphate Buffered Saline without calcium chloride and 
magnesium chloride (DPBS): 200 mg/L KCl, 200 mg/L KH2P0 4 , 
8000 mg/L NaCl, and 2,160 mg/L Na2HP04•7H20 or suitable diluent. 
Dulbecco's Phosphate Buffered Saline plus 0.05% w/v polysorbate 80 
(DPBST) or suitable diluent. Validated neutralizing agents/media 
as required (e.g . , Dey-Engley Neutralizing Broth and Agar). 
c. Test Equipment 
Sterile pipettes, glass beads, swabs, tubes, filters, etc., as 
required. Suitable instruments for spectrophotometric 
determination of cell density, for colony counting, and for 
centrifugation. 
D. Test Samples 
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Test product samples to be tested should be representative of the 
product to be marketed. Aliquots should be taken directly from 
the final product container immediately prior to testing. All 
regimen items, including cases, lenses, cleaning devices, etc., 
should be new and unused. If the test regimen results will be 
directly compared with results for a predicate device, then a 
predicate device from the same product category should be used for 
the comparison (e.g., a hydrogen peroxide product should be 
compared to a predicate hydrogen peroxide system and a multi-
purpose, product should be compared to a predicate multi-purpose 
product). Refer to Part 2:IV (PERFORMANCE REQUIREMENT). 
III. TEST METHODS 
A. Culture Maintenance 
Cultures should be maintained in the manner recommended by the 
curator of the appropriate culture collection. Cultures should be 
no greater than 5 passes removed from the depository stock (ATCC, 
NCIB, NCTC, NCPF or other recognized culture depository). 
B. Preparation of Microbial Challenge (Inoculum) 
Test organisms should be cultured and harvested as in 
Part l:III.B. 
After harvesting, organic soil consisting of heat killed yeast 
cells and heat inactivated serum, should be combined with the test 
organism to result in an initial concentration of 1 X 107 - 108 
cfu/ml. 
Prepare organic soil as follows. Culture s. cerevisiae on SDA at 
20-25°C for 48 hrs. Harvest as in Part 1:III.B. Heat kill the 
suspension at 100 ±2°C for 10 minutes. centrifuge at no more than 
5000 X g for a maximum of 30 minutes. Resuspend in bovine serum 
which has been heated at 56°C for 30 minutes to inactivate 
complement. The concentration of S. cerevisiae in serum should be 
1 X 10 7 - 108 • 
Centrifuge test organism suspension. 
a concentration 1 X 107 - 10 cfu/ml. 
used in the following procedure. 
Resuspend in organic soil to 
This is the inoculum to be 
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C. Test Procedure 
1. Lens Inoculation 
The test should be conducted with lens types representative 
of those with which the regimen is intended to be used 
(e.g., low water non-ionic, high water ionic, silicone 
acrylate, etc.). 
Inoculate eight lenses per lot of test product per microbial 
species tested; to qualify for all hydrophilic lenses use 
four (4) non-ionic low water lenses and four (4) ionic high 
water lenses. For hydrophobic lenses, use four (4) 
silicone-acrylate and four (4) fluorosilicone-acrylate 
lenses. 
organism 1 H;idroEhil i c Lenses 
Group I Material Group IV Material 
Lot 1 of Test Product 4 lenses 4 lenses 
Lot 2 of Test Product 4 lenses 4 lenses 
Lot 3 of Test Product 4 lenses 4 lenses 
12 lenses 12 lenses 
Organism 1 H;idroEhobic Lenses 
Lot 1 
Lot 2 
Lot 3 
Silicone-Acrylate Fluorosilicone-
Acrylate 
of Test Product 4 lenses 4 lenses 
of Test Product 4 lenses 4 lenses 
of Test Product 4 lenses 4 lenses 
12 lenses 12 lenses 
For hydrophilic or hydrophobic lenses, a total of 120 lenses 
(24 for each organism/60 lenses in each representative lens 
material) will be needed to test all 5 organisms. 
Place test and control lenses, concave surface uppermost in 
a sterile petri dish. 
Inoculate each lens by placing 0.01 ml of inoculum on the 
under surface of the lens at the point of contact between 
the petri dish and the lens, and 0.01 ml of inoculum on the 
top surface of the lens. 
Allow the inoculum to absorb to each lens for 5-10 min. at 
20-25°C. 
2. Lens Treatment 
After inoculum absorption, treat lenses as described in the 
manufacturer's consumer instructions for lens disinfection, 
including all steps of cleaning, rinsing and soaking 
specified by the manufacturer. Cleaning and rinsing 
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procedures (e.g., rubbing and rinsing times and rinse 
volumes} should be performed in identical fashion for the 
predicate device and the test sample, unless otherwise 
stated in the manufacturer's consumer instructions for lens 
care. Test protocols should specify these parameters. 
3. Recovery of surviving Challenge Organisms (e.g., Micro--
Appendix D Membrane Filtration Procedure} 
a. 
b. 
c. 
e. 
f. 
D. Controls 
Dispense suitable volume of validated neutralizing 
medium into filtration apparatus. 
Transfer entire content of each test lens case (lens 
and solution) into the neutralizing medium in the 
filtration apparatus. The neutralization exposure 
time prior to filtration should be determined in the 
validation study. 
Apply vacuum and filter solution. Rinse the filter 
two additional times with the neutralizing medium. 
Aseptically transfer the lens onto a bed of agar 
medium appropriate for recovery of the test organism. 
Pour 40-50°C agar medium (same as bed agar above} 
over the lens to cast it. 
Apply the test filter to the surface of a plate of 
appropriate solid media (could be the same as used in 
Part 2:III.C.3.d). 
Incubate bacterial recovery plates at 30-35°C for 2-4 
days. Incubate yeast recovery plates at 20-25°C or 
30-35°C for 3-5 days and mold recovery plates at 20-
250C for 3-7 days. 
1. Lens Inoculation Control 
For each microbial species tested transfer 3 inoculated 
lenses to tubes of TSB (for bacteria and yeasts} or SDB (for 
fungi} as appropriate. Vortex for 30 seconds. Serially 
dilute and plate out appropriate dilutions to permit a count 
of viable cells present. 
This count confirms that the number of organisms on the lens 
at the time of regimen challenge is adequate. The mean of 
the 3 counts should be not less than 2.0 X 105 • 
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2. Neutralization and Recovery Control 
Prepare filtration apparatus in triplicate (unless otherwise 
justified) as in Part 2:III.C.3 with suitable volumes of 
neutralizing medium and disinfecting solution. Add 5 to 50 
cfu of challenge organism, filter and cultivate as outlined 
in Part 2:III.C.3. 
Confirm inoculum on suitable medium in triplicate unless 
otherwise justified. 
The recovery in the neutralizer broth should be at least 50% 
of the inoculum. 
IV. PERFORMANCE REQUIREMENT 
Bacteria, molds and yeast .(See Table 2) 
Less than or equal to 10 cfu recovered from each lens and test filter 
combination for each test organism. Alternatively, the average number 
of surviving organisms recovered on the lens and the respective test 
filter should be shown to be substantially equivalent to results 
obtained for the predicate device(s) when tested according to this 
regimen procedure. organism counts (average for each organism) may be 
considered to be substantially equivalent if the difference between the 
subject device and the predicate device is less than or equal to 0.5 
log. 
' 
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Table 2 
SUMMARY OF RECOMMENDED PERFORMANCE 
CRITERIA FOR CONTACT LENS DISINFECTION PROCEDURES 
MEAN LOG REDUCTION AT DISINFECTION TIME 
PRODUCT FUNGI BACTERIA 
FSa CA SM PA SA 
Stand-Alone 1 1 3 3 3 
Criteria 
Regimen b b c c c 
Qualification 
Regimen d d d d d 
Criteria 
a FS = F. solani ATCC 36031, 
CA = c. albicans ATCC 10231, 
SM = s. marcescens ATCC 13880. 
PA = P. aeruginosa ATCC 9027, 
SA = s. au reus ATCC 6538 
b Stasis with an experimental error of ~0.5 log at the disinfection time. 
c The minimum acceptable log reduction for the mean value of all 3 
bacteria combined should be 5.0. The minimum acceptable log reduction 
for any single bacterial type should be 1.0. 
d Less than or equal to 10 cfu per lens and test filter combination from 
0.01 ml of 1 X 107 to 1 X 108 inoculum OR 
The average combined number of surviving organisms recovered on the len~ 
and the respective test filter must be shown to be substantially .1 
equivalent to the predicate device(s). 
I. PRINCIPLE 
MICRO--APPENDIX C 
BACTERIOSTASIS TEST 
lOS 
Bacteriostasis testing is performed for multi-dose saline products which 
do not contain conven~ional preservatives, yet do contain bacteriostatic 
agents (e.g., borate, boric acid, potassium sorbate, and EDTA ). For 
these products, which do not meet the preservative efficacy criteria 
described in Micro--Appendix A, a discard date should be determined on 
the basis of the product's bacteriostatic activity. The bacteriostasis 
test is a modification of the preservative efficacy test procedure. 
Three lots of product should be tested. Each lot of product should be 
tested with a separate inoculum preparation for each challenge organism . 
II. MATERIALS & REAGENTS 
A. Test Organisms 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Escherichia coli 
candida albicans 
Aspergillus niger 
B. Test Media 
NCIMB 8626 
NCTC 10788 
NCIB 8245 
NCPF 3179 
IMI 149007 
ATCC 9027 
ATCC 6538 
ATCC 8739 
ATCC 10231 
ATCC 16404 
Tryptone Soya Broth (TSB), Tryptone Soya Agar (TSA) , Sabouraud 
Dextrose Agar (SDA), Dulbecco's Phosphate Buffered Saline without 
calcium chloride and magnesium chloride (DPBS) : 200 mg/1 KCl, 200 
mg/1 KH2 P0 4 , 8000 mg/1 NaCl, and 2,160 mg/1 Na2HP0 4• 7H20 or suitable 
diluent 
Dulbecco's Phosphate Buffered Saline plus 0.05% w/v 
polysorbate 80 (DPBST) or suitable diluent 
Validated neutralizing agents/media as required (e.g., Dey-
Engley Neutralizing Broth and Agar). 
c . Test Equipment 
Sterile pipettes, glass beads, swabs , tubes, 100 X 20 mm petri 
dishes, etc., as required . suitable instruments for 
spectrophotometric determination of cell density, for colony 
counting, and for centrifugation. 
D. Test Samples 
Product samples to be tested should be representative of the 
product to be marketed. Prepare one tube containing a minimum of 
10 ml of test solution per challenge organism . The largest 
container size proposed for the product should be used. 
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III. TEST METHOD 
A. Culture Maintenance 
Cultures should be maintained in the manner recommended by the 
curator of the appropriate culture collection. Cultures should be 
no greater than 5 passes removed from the depository stock (ATCC, 
NCIB, NCTC, NCPF or other recognized culture depository) . 
B. Preparation of Microbial Challenge (Inoculum) 
Test organisms should be cultured on agar as in Table 1. 
Table 1: Media & Incubation Conditions for Growth of 
Challenge Organisms 
Organism Medium Incubation 
Temp oc Time 
Pseudomonas aeruginosa TSA 30-35 18-24h 
.I 
Staphylococcus aureus TSA 30-35 18-24h I Escherichia coli TSA 30-35 18-24h 
' Candida albicans SDA 20-25 42-48 or ~ 
SDA 30-35 18-24h ,, ;j 
Aspergillus niger SDA 20-25 7 days J 
To harvest all cultures, use sterile DPBST or a suitable diluent, 
washing the surface growth and transfer to a suitable vessel. The 
spore suspensions may be filtered through sterile glass wool, 
cotton gauze or cheese cloth to remove hypha! fragments. 
After harvesting, the cultured organisms may be washed using 
centrifugation. If centrifugation is used, each centrifugation 
should be conducted at 2-25°C for no longer than 10 minutes at 
4000 x g or less. The bacterial suspensions may be filtered ;1 
'r (e.g., 3 - 5 pro pore size) to produce a single cell dispersion. li 
All challenge cell suspensions should then be adjusted with DPBST ~ 
or other suitable diluent to 1 X 107 - 1 X 108 cfu/ml or cell Ill. 
concentration sufficient to result in final concentration of 1 X 
105 - 1 X 106 cfu/ml in the product. The approximate cell j 
concentration may be estimated by measuring the turbidity of th·= til 
suspension or a dilution of the suspension using a 
spectrophotometer. The actual concentration of cfu/ml should be 
determined for each _suspension by the plate count method at the ;Il 
time of the test. 
'I 
Bacterial and yeast cell suspensions should be used on the day of 
preparation. Bacterial and yeast cells may lose viability and 
resistance if not used on the day of preparation . Spore 
suspensions may be used up to 7 days following preparation by 
storage under refrigeration (Avg. 4~2°C}. 
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c. Test Procedure 
1. Inoculate the sample product to be tested with a suspension 
of test organisms sufficient to provide a final count of 1.0 
X 105 - 1.0 X 106 cfu/ml. The volume of inoculum should not 
exceed 1% of the sample volume. Ensure dispersion of the 
inoculum by adequate mixing. 
2. Store inoculated product at 20-25°C. Temperature should be 
monitored using a calibrated device and documented. If 
sensitive to light the product should be protected during 
the period of the test. 
3. Take 1.0 ml aliquots of the inoculated product for 
determination of viable count at 7, 14, 21, and 28 days. If 
longer discard dates are desired, continue sampling 
periodically thereafter. 
4. Subject 1.0 ml aliquots removed at the specified time 
intervals to a suitable series of decimal dilutions in 
validated neutralizing media. Mix suspension well by 
vortexing vigorously and incubate for a suitable period of 
time to allow for neutralization. 
If the antimicrobial agent(s) in the formulation cannot be 
adequately inactivated or neutralized it may be eliminated 
using a validated membrane filtration procedure (e.g., 
Micro-Appendix D) . 
5. Determine the viable count of organisms in appropriate 
dilutions by preparation of triplicate plates (unless 
otherwise justified) of suitable recovery medium (e.g., TSA 
for bacteria and SDA for mold and yeast). The agar for pour 
plates should be kept between 40-50°C prior to pouring. The 
agar media used for determination of viable counts may also 
contain antimicrobial inactivators or neutralizers if 
required. Where membrane filtration has been employed to 
remove/neutralize antimicrobial agents, membranes should be 
cultured on these media as appropriate. 
6. Incubate bacterial recovery plates at 30-35°C for 2-4 days. 
Incubate yeast at 20-25°C or 30-35°C for 3-5 days and mold 
recovery plates at 20-25°C for 3-7 days. 
7. Determine the average number of cfu on countable plates ar.d 
record. Countable plates refer to 30-300 cfu/plate for 
bacteria and yeast, and 8-80 cfu!plate for mold except wher. 
colonies are observed only for 10 or 10-1 dilution plates. 
Calculate microbial reduction at the specified time points. 
8. The concentration of survivors should be calculated at each 
time point. 
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D. controls 
1. Inoculum Controls 
The initial inoculum concentration should be calculated by 
dispersing an identical aliquot of the inoculum into the 
same volume of a suitable diluent (e.g., DPBST ) as used in 
III.C.1 to achieve a final concentration of 1.0 X 105 -
1.0 X 106 cfu/ml. Ensure dispersion of the inoculum by 
adequate mixing. This control sample should be evaluated at 
the same time as the zero time sample. This serves to 
demonstrate the suitability of the medium used for growth of 
the test organism and provides an estimate of the initial 
inoculum concentration. 
2. Recovery Medium Control 
Qualify the neutralizing agent/medium for the product 
initially and periodically thereafter. Prepare a 1/10 
dilution of the product in the validated neutralizing broth 
(1 ml into 9 ml). If a greater dilution of the test 
solution is required to achieve neutralization, the latter 
dilution should be used. Prepare a second control tube with 
10 ml of a suitable diluent (e.g., TSB). Inoculate the 
tubes with sufficient inoculum to result in 10 - 100 cfu of 
challenge organism per plate. Incubate for an appropriate 
period of time at ambient temperature. Plate the 
appropriate aliquot from each tube onto the recovery agar 
plates in triplicate unless otherwise justified. The 
recovery in the neutralizer broth should be at least 50% ·::lt 
the recovery in the second control tube. This control is to 
be performed for each challenge organism. 
IV. PERFORMANCE CRITERIA 
A. Bacteria 
The concentration of each bacterial challenge organism 
should remain at the initial level or decrease. 
B. Molds and Yeasts 
The concentration of the yeast and mold should remain at 
initial levels or decrease within an experimental error of 
_:0.5 log. 
c. The product should be labeled to discard the container after 
it has been opened for the number of days which corresponds 
to time point previous to the point at which any organism 
shows an increase in number (see example). The container 
label should include a space on which to record the date 
opened. 
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Examp l e : 
(Concentration in Abbreviated Log Value ) 
DAY 
0 7 14 21 28 35 
E. coli 105 10 3 <10 10 1 102 103 
P. aeru. 10 5 103 103 10 2 103 10 4 
s. aureus 105 <10 <10 <10 <10 <10 
c . alb. lOs lOs 104 102 <10 <10 
A. niger 105 10 4 103 10 4 10 4 105 
cut off point: E. coli 14 days 
P. aeru. 21 days 
A. niger 14 days 
The use of the above hypothetical product is limited to 14 
days after opening. 
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AA ioalaphotdk IIU1IC:tUre ~~ Racdic:al dcvica C. pro-
vided that 111ei COAlnJllcd eJectricaJ c:vm:n1 dl:rind 
from two diuimiJar .Uvuie matet'iak to driw OIIF<fy-
IWIIic metal laar bu.o tOlllliott 10 kill ~ 011 t.lld 
aetr the dtmce to wllieh the itJlK:1W'C b affiud. ln one 
em~ a lint plv.nic material aapanted frosn • 
seco1ld plvuic m.tc:rW b:y a caimve JO&terial pro-
41l0CS &1\ uri~rial CUJTCDt flow when placM. iG 
COilW!l with ~ deeuo\ytie nuid. In anDthd- azabadi· 
tacllt. a cyliD4dcaJ clastoza.eric ~tbc:tc:r NwoJpOnlles 1. 
fim and a sc:ooad alll...UC matedat tqDBted b)' • Jais-
ti,.oe material which CODtrms a cvrreat flow between the 
&alvuio matariah who the catheter is imau=neclla AA 
clc:cttn&ytic fluid. The Jalvatdc: materials CID be d!s$imi-
W maal pOWders~ ia a amducdvw; pai)'DlU 
substtate that rora u iomoptm-dic c:ampoat.e JNte-
rial. or Crcjmiltr metals arnugcd in laycm ~ by 
a rmilriw la~.IR fe\ aocher ~It the ionto. 
pharcdt c:ompnd(c ~ ii amfaprai u an Wee. 
tlcm COiltrol ~that coven • ponicm ar &11 ~
c&tbtUt or cwnala .. .Mdhods or pcotmms impJansaN-e 
JhCdical dii!VW& uac1 body ctnJd\U'eS with the iontapbo-
ruie 'IIU\Idurcs are abo provided. 
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